NCT01998542View on ClinicalTrials.gov

Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 1, 2017

Study Completion Date

November 30, 2017

Conditions
Cancer of Head and NeckSquamous Cell Carcinoma of the Head and Neck
Interventions
BIOLOGICAL

AlloVax

Personalized anti-cancer vaccine with AlloStim(TM) and CRCL

BIOLOGICAL

CRCL

autologous tumor-derived chaperone protein mixture

BIOLOGICAL

AlloStim

AlloStim (ID) injection AlloStim (IV) infusion

Trial Locations (1)

Unknown

National Cancer Institute of Thailand, Bangkok

Sponsors
All Listed Sponsors
lead

Mirror Biologics, Inc.

INDUSTRY

NCT01998542 - Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck | Biotech Hunter | Biotech Hunter